Předmět: |
|
Zdroj: |
Immunotherapy Weekly; 11/26/2024, p482-482, 1p |
Abstrakt: |
A study conducted at Hunan Cancer Hospital in the People's Republic of China evaluated the effectiveness and safety of neoadjuvant immunotherapy for patients with non-small cell lung cancer (NSCLC). The meta-analysis of eleven randomized controlled trials showed that neoadjuvant immunochemotherapy had better clinical efficacy than neoadjuvant chemotherapy for NSCLC patients. The study concluded that the long-term survival outcomes of neoadjuvant immunotherapy need further confirmation to guide clinical practice. [Extracted from the article] |
Databáze: |
Complementary Index |
Externí odkaz: |
|